Regeneron Pharmaceuticals, Inc. (REGN)
USD 581.68
(-4.74%)
USD 581.68
(-4.74%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -27.1 Million USD | 93.3% |
| 2022 | -404.5 Million USD | -117.59% |
| 2021 | -185.9 Million USD | -137.03% |
| 2020 | 502 Million USD | 155.54% |
| 2019 | -903.9 Million USD | -19.06% |
| 2018 | -759.2 Million USD | -594.73% |
| 2017 | -109.28 Million USD | -102.08% |
| 2016 | -54.07 Million USD | 87.53% |
| 2015 | -433.59 Million USD | -128.62% |
| 2014 | -189.65 Million USD | -530.17% |
| 2013 | -30.09 Million USD | -113.26% |
| 2012 | 227.05 Million USD | 572.27% |
| 2011 | -48.07 Million USD | -201.3% |
| 2010 | 47.45 Million USD | 122.92% |
| 2009 | -207.07 Million USD | 14.68% |
| 2008 | -242.7 Million USD | 18.18% |
| 2007 | -296.63 Million USD | -683.17% |
| 2006 | -37.87 Million USD | -344.49% |
| 2005 | 15.49 Million USD | -84.31% |
| 2004 | 98.76 Million USD | 3.39% |
| 2003 | 95.53 Million USD | -20.44% |
| 2002 | 120.07 Million USD | 356.47% |
| 2001 | -46.81 Million USD | -65.45% |
| 2000 | -28.29 Million USD | -44.37% |
| 1999 | -19.6 Million USD | -25.64% |
| 1998 | -15.6 Million USD | 33.05% |
| 1997 | -23.3 Million USD | 9.69% |
| 1996 | -25.8 Million USD | -11.21% |
| 1995 | -23.2 Million USD | -105.31% |
| 1994 | -11.3 Million USD | -126.0% |
| 1993 | -5 Million USD | 47.92% |
| 1992 | -9.6 Million USD | 58.97% |
| 1991 | -23.4 Million USD | -7.34% |
| 1990 | -21.8 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 775.4 Million USD | 665.45% |
| 2024 Q1 | 101.3 Million USD | 473.8% |
| 2024 Q3 | 692.2 Million USD | -10.73% |
| 2023 Q1 | -1.21 Billion USD | -200.25% |
| 2023 Q4 | -27.1 Million USD | -104.92% |
| 2023 FY | -27.1 Million USD | 93.3% |
| 2023 Q2 | 765 Million USD | 162.99% |
| 2023 Q3 | 550.3 Million USD | -28.07% |
| 2022 Q2 | -694.4 Million USD | -7.61% |
| 2022 Q3 | -790.2 Million USD | -13.8% |
| 2022 FY | -404.5 Million USD | -117.59% |
| 2022 Q1 | -645.3 Million USD | -247.12% |
| 2022 Q4 | -404.5 Million USD | 48.81% |
| 2021 FY | -185.9 Million USD | -137.03% |
| 2021 Q2 | 625.4 Million USD | -50.32% |
| 2021 Q1 | 1.25 Billion USD | 150.76% |
| 2021 Q3 | -733.8 Million USD | -217.33% |
| 2021 Q4 | -185.9 Million USD | 74.67% |
| 2020 Q2 | 223.7 Million USD | 114.98% |
| 2020 FY | 502 Million USD | 155.54% |
| 2020 Q1 | -1.49 Billion USD | -65.17% |
| 2020 Q4 | 502 Million USD | -55.25% |
| 2020 Q3 | 1.12 Billion USD | 401.48% |
| 2019 FY | -903.9 Million USD | -19.06% |
| 2019 Q1 | -998.6 Million USD | -31.53% |
| 2019 Q2 | -334.2 Million USD | 66.53% |
| 2019 Q4 | -903.9 Million USD | -34.49% |
| 2019 Q3 | -672.1 Million USD | -101.11% |
| 2018 Q4 | -759.2 Million USD | -99.45% |
| 2018 FY | -759.2 Million USD | -594.73% |
| 2018 Q3 | -380.64 Million USD | -79.57% |
| 2018 Q2 | -211.97 Million USD | 32.67% |
| 2018 Q1 | -314.84 Million USD | -188.11% |
| 2017 FY | -109.28 Million USD | -102.08% |
| 2017 Q4 | -109.28 Million USD | -21.76% |
| 2017 Q1 | -104.16 Million USD | -92.63% |
| 2017 Q2 | -43.14 Million USD | 58.59% |
| 2017 Q3 | -89.74 Million USD | -108.04% |
| 2016 Q3 | -538.13 Million USD | -88.83% |
| 2016 Q4 | -54.07 Million USD | 89.95% |
| 2016 Q2 | -284.98 Million USD | -17.77% |
| 2016 Q1 | -241.98 Million USD | 44.19% |
| 2016 FY | -54.07 Million USD | 87.53% |
| 2015 Q4 | -433.59 Million USD | -66.95% |
| 2015 Q3 | -259.72 Million USD | -10259.79% |
| 2015 Q1 | -35.43 Million USD | 81.32% |
| 2015 FY | -433.59 Million USD | -128.62% |
| 2015 Q2 | -2.5 Million USD | 92.92% |
| 2014 FY | -189.65 Million USD | -530.17% |
| 2014 Q1 | 69.25 Million USD | 330.11% |
| 2014 Q2 | -82.28 Million USD | -218.82% |
| 2014 Q3 | -81.24 Million USD | 1.27% |
| 2014 Q4 | -189.65 Million USD | -133.45% |
| 2013 Q4 | -30.09 Million USD | -113.74% |
| 2013 FY | -30.09 Million USD | -113.26% |
| 2013 Q1 | 282.38 Million USD | 24.37% |
| 2013 Q2 | 91.62 Million USD | -67.55% |
| 2013 Q3 | 218.96 Million USD | 138.97% |
| 2012 Q1 | 46.24 Million USD | 196.2% |
| 2012 Q2 | 274.28 Million USD | 493.08% |
| 2012 Q3 | 332.73 Million USD | 21.31% |
| 2012 FY | 227.05 Million USD | 572.27% |
| 2012 Q4 | 227.05 Million USD | -31.76% |
| 2011 Q2 | -93.97 Million USD | -479.33% |
| 2011 FY | -48.07 Million USD | -201.3% |
| 2011 Q4 | -48.07 Million USD | -4.53% |
| 2011 Q3 | -45.99 Million USD | 51.06% |
| 2011 Q1 | 24.77 Million USD | -47.8% |
| 2010 Q1 | 39.58 Million USD | 119.12% |
| 2010 FY | 47.45 Million USD | 122.92% |
| 2010 Q4 | 47.45 Million USD | 128.54% |
| 2010 Q3 | -166.27 Million USD | -462.98% |
| 2010 Q2 | 45.8 Million USD | 15.71% |
| 2009 Q4 | -207.07 Million USD | -10.29% |
| 2009 FY | -207.07 Million USD | 14.68% |
| 2009 Q1 | -199.09 Million USD | 17.97% |
| 2009 Q2 | -208.54 Million USD | -4.74% |
| 2009 Q3 | -187.75 Million USD | 9.97% |
| 2008 Q1 | -320.87 Million USD | -8.17% |
| 2008 FY | -242.7 Million USD | 18.18% |
| 2008 Q2 | -173.47 Million USD | 45.94% |
| 2008 Q3 | -197.18 Million USD | -13.66% |
| 2008 Q4 | -242.7 Million USD | -23.09% |
| 2007 Q1 | 43.51 Million USD | 214.89% |
| 2007 FY | -296.63 Million USD | -683.17% |
| 2007 Q3 | 102.58 Million USD | 13.53% |
| 2007 Q2 | 90.35 Million USD | 107.64% |
| 2007 Q4 | -296.63 Million USD | -389.16% |
| 2006 Q1 | 17.66 Million USD | 14.05% |
| 2006 Q3 | 32.33 Million USD | -61.97% |
| 2006 FY | -37.87 Million USD | -344.49% |
| 2006 Q4 | -37.87 Million USD | -217.13% |
| 2006 Q2 | 85.04 Million USD | 381.32% |
| 2005 Q4 | 15.49 Million USD | -35.2% |
| 2005 Q3 | 23.9 Million USD | -56.37% |
| 2005 FY | 15.49 Million USD | -84.31% |
| 2005 Q2 | 54.79 Million USD | 5.01% |
| 2005 Q1 | 52.18 Million USD | -47.16% |
| 2004 Q3 | 94.95 Million USD | 23.05% |
| 2004 FY | 98.76 Million USD | 3.39% |
| 2004 Q4 | 98.76 Million USD | 4.02% |
| 2004 Q1 | 25.96 Million USD | -72.82% |
| 2004 Q2 | 77.16 Million USD | 197.18% |
| 2003 Q3 | -89.32 Million USD | -218.32% |
| 2003 Q2 | 75.48 Million USD | 790.71% |
| 2003 Q4 | 95.53 Million USD | 206.95% |
| 2003 FY | 95.53 Million USD | -20.44% |
| 2003 Q1 | 8.47 Million USD | -92.94% |
| 2002 Q1 | 64.99 Million USD | 238.83% |
| 2002 Q3 | 124.66 Million USD | -4.8% |
| 2002 Q2 | 130.95 Million USD | 101.47% |
| 2002 FY | 120.07 Million USD | 356.47% |
| 2002 Q4 | 120.07 Million USD | -3.68% |
| 2001 Q1 | -181.16 Million USD | -540.24% |
| 2001 Q4 | -46.81 Million USD | 52.13% |
| 2001 Q3 | -97.8 Million USD | 30.46% |
| 2001 Q2 | -140.63 Million USD | 22.37% |
| 2001 FY | -46.81 Million USD | -65.45% |
| 2000 FY | -28.29 Million USD | -44.37% |
| 2000 Q4 | -28.29 Million USD | 39.33% |
| 2000 Q3 | -46.63 Million USD | 40.44% |
| 2000 Q2 | -78.3 Million USD | -829.81% |
| 2000 Q1 | -8.42 Million USD | 57.03% |
| 1999 Q2 | -16.9 Million USD | 5.59% |
| 1999 FY | -19.6 Million USD | -25.64% |
| 1999 Q4 | -19.6 Million USD | 2.97% |
| 1999 Q3 | -20.2 Million USD | -19.53% |
| 1999 Q1 | -17.9 Million USD | -14.74% |
| 1998 Q4 | -15.6 Million USD | 13.81% |
| 1998 Q1 | -14.5 Million USD | 37.77% |
| 1998 Q2 | -17.7 Million USD | -22.07% |
| 1998 Q3 | -18.1 Million USD | -2.26% |
| 1998 FY | -15.6 Million USD | 33.05% |
| 1997 Q2 | -44.1 Million USD | -119.4% |
| 1997 Q3 | -33.5 Million USD | 24.04% |
| 1997 Q4 | -23.3 Million USD | 30.45% |
| 1997 Q1 | -20.1 Million USD | 22.09% |
| 1997 FY | -23.3 Million USD | 9.69% |
| 1996 Q2 | -40.3 Million USD | -1159.38% |
| 1996 Q1 | -3.2 Million USD | 86.21% |
| 1996 FY | -25.8 Million USD | -11.21% |
| 1996 Q3 | -28.5 Million USD | 29.28% |
| 1996 Q4 | -25.8 Million USD | 9.47% |
| 1995 FY | -23.2 Million USD | -105.31% |
| 1995 Q1 | -4 Million USD | 64.6% |
| 1995 Q3 | 4.4 Million USD | 175.86% |
| 1995 Q2 | -5.8 Million USD | -45.0% |
| 1995 Q4 | -23.2 Million USD | -627.27% |
| 1994 FY | -11.3 Million USD | -126.0% |
| 1994 Q4 | -11.3 Million USD | -126.0% |
| 1994 Q2 | -8.6 Million USD | -320.51% |
| 1994 Q1 | 3.9 Million USD | 178.0% |
| 1994 Q3 | -5 Million USD | 41.86% |
| 1993 Q2 | -100 Thousand USD | 95.83% |
| 1993 Q4 | -5 Million USD | 84.38% |
| 1993 FY | -5 Million USD | 47.92% |
| 1993 Q3 | -32 Million USD | -31900.0% |
| 1993 Q1 | -2.4 Million USD | 75.0% |
| 1992 Q2 | -16.3 Million USD | 18.91% |
| 1992 FY | -9.6 Million USD | 58.97% |
| 1992 Q4 | -9.6 Million USD | 26.15% |
| 1992 Q1 | -20.1 Million USD | 14.1% |
| 1992 Q3 | -13 Million USD | 20.25% |
| 1991 Q3 | -34.2 Million USD | 11.86% |
| 1991 Q2 | -38.8 Million USD | 0.0% |
| 1991 FY | -23.4 Million USD | -7.34% |
| 1991 Q4 | -23.4 Million USD | 31.58% |
| 1990 Q4 | -21.8 Million USD | 0.0% |
| 1990 FY | -21.8 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | -55.94 Million USD | 51.555% |
| Alkermes plc | -166.73 Million USD | 83.747% |
| Agenus Inc. | 274.13 Million USD | 109.886% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 101.449% |
| Aptorum Group Limited | 1.35 Million USD | 2096.985% |
| Ardelyx, Inc. | 34.51 Million USD | 178.523% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | 733.178% |
| Bicycle Therapeutics plc | -481.46 Million USD | 94.371% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | 174.938% |
| ChromaDex Corporation | -24.04 Million USD | -12.691% |
| Chimerix, Inc. | -25.51 Million USD | -6.204% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 488.917% |
| Caribou Biosciences, Inc. | -23.67 Million USD | -14.457% |
| CRISPR Therapeutics AG | -150.84 Million USD | 82.035% |
| Precision BioSciences, Inc. | -85.41 Million USD | 68.271% |
| Dyadic International, Inc. | -6.37 Million USD | -324.891% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | -70.087% |
| Fortress Biotech, Inc. | 7.66 Million USD | 453.555% |
| Lantern Pharma Inc. | -21.7 Million USD | -24.866% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 75.483% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | -217.212% |
| Incyte Corporation | -3.17 Billion USD | 99.146% |
| IO Biotech, Inc. | -140.69 Million USD | 80.739% |
| Jaguar Health, Inc. | 29.39 Million USD | 192.205% |
| Novavax, Inc. | -298.29 Million USD | 90.915% |
| Janux Therapeutics, Inc. | 5.33 Million USD | 607.776% |
| Opthea Limited | 28.15 Million USD | 196.245% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | -61.415% |
| ContextLogic Inc. | -232 Million USD | 88.319% |
| MiMedx Group, Inc. | -33.9 Million USD | 20.061% |
| Pyxis Oncology, Inc. | 10.19 Million USD | 365.817% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | -1069.602% |
| NextCure, Inc. | -6.47 Million USD | -318.404% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 46.338% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | -324.831% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | 322.802% |
| Vaxcyte, Inc. | -368.22 Million USD | 92.64% |
| PDS Biotechnology Corporation | -32.7 Million USD | 17.148% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | 256.847% |
| Pharming Group N.V. | 109.8 Million USD | 124.68% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | -55.783% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 84.535% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | -46.329% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | -46.329% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -281.69% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | -362.457% |
| Acelyrin, Inc. | -216.9 Million USD | 87.506% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | -383.043% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | -1471.926% |
| Summit Therapeutics Inc. | 34.67 Million USD | 178.157% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | -298.354% |
| Senti Biosciences, Inc. | 1.74 Million USD | 1657.471% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 85.32% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 65.01% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | -347.047% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | 27262.746% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | 4415.287% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 76.847% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 83.891% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 124.443% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | -256.767% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 79.011% |
| Psyence Biomedical Ltd. | 6.89 Million USD | 493.061% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 88.818% |
| Immix Biopharma, Inc. | -17.5 Million USD | -54.771% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 91.443% |
| MEI Pharma, Inc. | -3.7 Million USD | -631.444% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | 316.609% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 116.755% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | 197.507% |
| Fortress Biotech, Inc. | 7.66 Million USD | 453.555% |
| Precigen, Inc. | -481 Thousand USD | -5534.096% |
| Clearside Biomedical, Inc. | 14.08 Million USD | 292.458% |
| AlloVir, Inc. | -62.69 Million USD | 56.773% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 51.271% |
| Fate Therapeutics, Inc. | 61.66 Million USD | 143.946% |
| ImmuCell Corporation | 10.99 Million USD | 346.575% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 82.419% |
| Onconetix, Inc. | 5.33 Million USD | 608.306% |
| PureTech Health plc | -167.19 Million USD | 83.792% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 11.031% |
| Elevation Oncology, Inc. | -19.11 Million USD | -41.751% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | -452.047% |
| Seer, Inc. | -4.24 Million USD | -539.151% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | -12.743% |
| Innoviva, Inc. | 255.56 Million USD | 110.604% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 51.489% |
| ESSA Pharma Inc. | -33.62 Million USD | 19.397% |
| GlycoMimetics, Inc. | -40.98 Million USD | 33.877% |
| GT Biopharma, Inc. | -1.02 Million USD | -2554.261% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 60.019% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | 144.24% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 79.788% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | -95.583% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 6.137% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | -35873.133% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 12.19% |
| Aptose Biosciences Inc. | -8.19 Million USD | -230.695% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | -766.086% |
| Soligenix, Inc. | -4.95 Million USD | -447.298% |
| Century Therapeutics, Inc. | 847 Thousand USD | 3299.528% |
| Kura Oncology, Inc. | -20.11 Million USD | -34.705% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 33.783% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | -222.696% |
| Ocean Biomedical, Inc. | 1.82 Million USD | 1587.626% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | -747.67% |
| Autolus Therapeutics plc | -186.59 Million USD | 85.477% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 45.035% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 90.174% |
| Eterna Therapeutics Inc. | 34.26 Million USD | 179.083% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | 116.487% |
| GRI Bio, Inc. | -1.79 Million USD | -1410.591% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | -201.679% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 18.513% |
| IGM Biosciences, Inc. | -72.6 Million USD | 62.675% |
| INmune Bio, Inc. | -25.41 Million USD | -6.647% |
| Heron Therapeutics, Inc. | 150.95 Million USD | 117.953% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 46.505% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | -66.776% |
| Entero Therapeutics, Inc. | -2.88 Million USD | -839.366% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | 171.288% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 34.199% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 184.993% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 107.17% |
| Verastem, Inc. | -37.27 Million USD | 27.303% |
| Abeona Therapeutics Inc. | -9.07 Million USD | -198.688% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 47.746% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | -79.055% |
| Histogen Inc. | -7.48 Million USD | -261.961% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | -25.423% |
| Surrozen, Inc. | -32.66 Million USD | 17.034% |
| Organovo Holdings, Inc. | -1.5 Million USD | -1698.275% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | -544.703% |
| Ovid Therapeutics Inc. | 18.96 Million USD | 242.931% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | 1135.933% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | 752.069% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | -223.345% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 37.618% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | -85.911% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 91.445% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | -3653.151% |
| Apollomics, Inc. | -27.39 Million USD | 1.077% |
| Amarin Corporation plc | -191.04 Million USD | 85.814% |
| Mesoblast Limited | 55.96 Million USD | 148.425% |
| Turnstone Biologics Corp. | -14.58 Million USD | -85.82% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | -7.149% |
| Synaptogenix, Inc. | -28.66 Million USD | 5.448% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | -2795.299% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | 155.61% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | -3043.527% |
| Monopar Therapeutics Inc. | -7.26 Million USD | -272.966% |
| Exelixis, Inc. | -73.05 Million USD | 62.902% |
| Better Therapeutics, Inc. | -860 Thousand USD | -3051.163% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | -12.856% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 88.772% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | 3781.735% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | -264.339% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | 2261.085% |
| Gritstone bio, Inc. | 39.49 Million USD | 168.625% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 67.777% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | -929.58% |
| Avid Bioservices, Inc. | 169.72 Million USD | 115.967% |
| Insmed Incorporated | 721.62 Million USD | 103.755% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | -196.45% |
| MediWound Ltd. | -5.32 Million USD | -409.207% |
| OmniAb, Inc. | 9.2 Million USD | 394.469% |
| Alector, Inc. | -35.63 Million USD | 23.955% |
| Seres Therapeutics, Inc. | 85.97 Million USD | 131.522% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | -449.919% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 304.698% |
| Zai Lab Limited | -775 Million USD | 96.503% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 107.958% |
| Aura Biosciences, Inc. | -21.52 Million USD | -25.9% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 67.144% |
| Immunic, Inc. | -45.34 Million USD | 40.229% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 85.974% |
| Veracyte, Inc. | -203.82 Million USD | 86.704% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 104.246% |
| FibroGen, Inc. | 56.76 Million USD | 147.739% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 404.323% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | -858.586% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | -1208.959% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 100.59% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | -711.134% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 83.671% |
| TG Therapeutics, Inc. | 17.86 Million USD | 251.719% |
| Galecto, Inc. | -21.21 Million USD | -27.734% |
| Calithera Biosciences, Inc. | -23.78 Million USD | -13.937% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 101.727% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | -10.739% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | -135.509% |
| XBiotech Inc. | -200.02 Million USD | 86.452% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 67.777% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | 698.498% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 23.149% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 64.905% |
| Theravance Biopharma, Inc. | 5.69 Million USD | 576.19% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 84.098% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 70.663% |
| Vaxxinity, Inc. | 10.13 Million USD | 367.469% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 103.681% |
| Gain Therapeutics, Inc. | -10.76 Million USD | -151.682% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 58.912% |
| NexImmune, Inc. | -3.13 Million USD | -764.808% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | -684.899% |
| Marker Therapeutics, Inc. | -15.11 Million USD | -79.334% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | -201.914% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | -21653.963% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 33.205% |
| Ainos, Inc. | 4.07 Million USD | 764.553% |
| Pluri Inc. | 22.82 Million USD | 218.709% |
| Prothena Corporation plc | -608.34 Million USD | 95.545% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 77.18% |
| Celularity Inc. | 65.19 Million USD | 141.571% |
| Rallybio Corporation | -24.1 Million USD | -12.439% |
| Cue Biopharma, Inc. | -33.81 Million USD | 19.868% |
| MeiraGTx Holdings plc | -40.3 Million USD | 32.758% |
| Omeros Corporation | 331.17 Million USD | 108.183% |
| Humacyte, Inc. | -22.48 Million USD | -20.519% |
| Immunocore Holdings plc | -358.59 Million USD | 92.443% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | -10.275% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 12.301% |
| Blueprint Medicines Corporation | 702.83 Million USD | 103.856% |
| CalciMedica, Inc. | -5.53 Million USD | -390.054% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 85.602% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | -165.322% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 32.313% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 18.504% |
| Pulmatrix, Inc. | -10.41 Million USD | -160.152% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | -353.405% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 28.95% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 75.674% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 54.791% |
| Cytokinetics, Incorporated | 642.37 Million USD | 104.219% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | -365.396% |
| Nutriband Inc. | -251.65 Thousand USD | -10668.626% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 20.572% |
| Vor Biopharma Inc. | 4.3 Million USD | 730.233% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 99.551% |
| Evogene Ltd. | -19.63 Million USD | -38.026% |
| ProKidney Corp. | -56.23 Million USD | 51.81% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 44.321% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | -193.379% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 101.987% |
| CorMedix Inc. | -43.05 Million USD | 37.054% |
| BioLineRx Ltd. | 7.33 Million USD | 469.411% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 1.329% |
| Galectin Therapeutics Inc. | 46.14 Million USD | 158.725% |
| Atai Life Sciences N.V. | -28.55 Million USD | 5.105% |
| Renovaro Biosciences Inc. | 2.23 Million USD | 1314.958% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | -18.776% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | 252.805% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 63.902% |
| MediciNova, Inc. | -50.78 Million USD | 46.636% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 65.611% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | -120371.216% |
| GeoVax Labs, Inc. | -6.45 Million USD | -319.986% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 86.438% |
| Biomea Fusion, Inc. | -166.57 Million USD | 83.731% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 84.858% |
| Mereo BioPharma Group plc | -51.46 Million USD | 47.347% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 71.427% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 90.775% |
| Absci Corporation | -72.59 Million USD | 62.671% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 693.517% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 88.44% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 71.235% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 71.681% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 30.643% |
| Allakos Inc. | -24.97 Million USD | -8.509% |
| Imunon, Inc. | -4.21 Million USD | -543.117% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | -83.829% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 79.985% |
| BioAtla, Inc. | -109.01 Million USD | 75.14% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | 3781.735% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | -2786.049% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | 326.475% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | -27.812% |
| XOMA Corporation | -29 Million USD | 6.552% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | -63.647% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -200.577% |
| aTyr Pharma, Inc. | -7.44 Million USD | -263.807% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 78.257% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 86.981% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 66.862% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 70.786% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | -3054.156% |
| Akari Therapeutics, Plc | -3.84 Million USD | -604.811% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | 1769.861% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 101.963% |
| Lexaria Bioscience Corp. | -1.18 Million USD | -2180.886% |
| UroGen Pharma Ltd. | 4.39 Million USD | 717.171% |
| Sutro Biopharma, Inc. | 113.48 Million USD | 123.881% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | 37758.764% |
| Orgenesis Inc. | 21.78 Million USD | 224.403% |
| Entera Bio Ltd. | -10.62 Million USD | -154.963% |
| GH Research PLC | -78.07 Million USD | 65.291% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | -21.59% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | -1.654% |
| Xencor, Inc. | 29.64 Million USD | 191.418% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | -1275.766% |
| Replimune Group, Inc. | 1.41 Million USD | 2019.263% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | -10965.38% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 78.563% |
| Lexaria Bioscience Corp. | -1.18 Million USD | -2180.886% |
| Portage Biotech Inc. | -4.98 Million USD | -444.067% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | -120371.216% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 59.015% |
| OncoCyte Corporation | -6.56 Million USD | -312.921% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | 3119.791% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | -494.867% |
| Purple Biotech Ltd. | -14.13 Million USD | -91.682% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | -14.076% |
| scPharmaceuticals Inc. | -6.54 Million USD | -314.057% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | -62.352% |
| HilleVax, Inc. | -165.48 Million USD | 83.624% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | -967.77% |
| Tharimmune, Inc. | -10.93 Million USD | -147.82% |
| Genprex, Inc. | -6.73 Million USD | -302.219% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 92.652% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 69.365% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | -1834.333% |
| Virios Therapeutics, Inc. | -3.31 Million USD | -717.017% |
| OKYO Pharma Limited | -826.84 Thousand USD | -3177.507% |
| Savara Inc. | 153 Thousand USD | 17812.418% |
| Curis, Inc. | -23.88 Million USD | -13.451% |
| Daré Bioscience, Inc. | -5.15 Million USD | -425.407% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | -3392.214% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | -336.534% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | 2386.92% |
| BeiGene, Ltd. | -2.25 Billion USD | 98.797% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 319.638% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 95.544% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 85.398% |
| Erasca, Inc. | -37.21 Million USD | 27.182% |
| bluebird bio, Inc. | 108.57 Million USD | 124.961% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | -2004.212% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 107.155% |
| DBV Technologies S.A. | -126.98 Million USD | 78.659% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | -2004.212% |
| Moderna, Inc. | -2.9 Billion USD | 99.068% |
| Vincerx Pharma, Inc. | -10.35 Million USD | -161.785% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | -149.356% |
| Molecular Templates, Inc. | 707 Thousand USD | 3933.098% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 13.614% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 107.819% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 66.976% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 70.457% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 16.026% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 21.166% |
| MacroGenics, Inc. | -66.98 Million USD | 59.543% |
| RenovoRx, Inc. | -1.17 Million USD | -2210.315% |
| Adicet Bio, Inc. | -138.78 Million USD | 80.474% |
| Prime Medicine, Inc. | -27.94 Million USD | 3.01% |
| Aditxt, Inc. | 18.12 Million USD | 249.551% |
| Adagene Inc. | -87.62 Million USD | 69.074% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | -550.593% |
| Quantum-Si incorporated | -118.55 Million USD | 77.142% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | 175.267% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | -262.581% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 44.134% |
| SciSparc Ltd. | -2.06 Million USD | -1212.349% |
| Vericel Corporation | 1.27 Million USD | 2222.161% |
| Revelation Biosciences, Inc. | -11.99 Million USD | -125.99% |
| Minerva Neurosciences, Inc. | 41 Million USD | 166.091% |
| Generation Bio Co. | 31.44 Million USD | 186.174% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 84.546% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 12.363% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | 123.243% |
| Invivyd, Inc. | -198.47 Million USD | 86.346% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 69.979% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | -1030.255% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 61.718% |
| Artelo Biosciences, Inc. | -6.82 Million USD | -297.07% |
| 2seventy bio, Inc. | 181.71 Million USD | 114.913% |
| ADMA Biologics, Inc. | 90.06 Million USD | 130.089% |
| Clene Inc. | 3.34 Million USD | 911.377% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | -198.369% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | -25.982% |
| GeoVax Labs, Inc. | -6.45 Million USD | -319.986% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 92.125% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | -4.232% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | 115.253% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | -562.338% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 641.783% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | -420.253% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 79.202% |
| Evaxion Biotech A/S | 5.28 Million USD | 612.593% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 75.926% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 79.356% |
| Trevena, Inc. | 2.25 Million USD | 1300.177% |
| Surrozen, Inc. | -32.66 Million USD | 17.034% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 47.389% |
| Cingulate Inc. | 3.08 Million USD | 979.104% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | -822.71% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 477.07% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | -191.673% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 65.836% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 79.384% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 74.323% |
| Clearmind Medicine Inc. | -3.94 Million USD | -587.357% |
| Kronos Bio, Inc. | -36.05 Million USD | 24.835% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | 388.022% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | 1958.549% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 50.052% |
| Statera Biopharma, Inc. | 14.41 Million USD | 287.98% |
| ImmunityBio, Inc. | 618.22 Million USD | 104.384% |
| Korro Bio, Inc. | -132.94 Million USD | 79.615% |
| Kineta, Inc. | -4.54 Million USD | -496.785% |
| BioVie Inc. | -17.73 Million USD | -52.828% |
| Codexis, Inc. | -43.27 Million USD | 37.371% |
| Celularity Inc. | 65.19 Million USD | 141.571% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | -755.159% |
| Celcuity Inc. | 6.78 Million USD | 499.498% |
| Virax Biolabs Group Limited | -3.36 Million USD | -705.363% |
| Cibus, Inc. | -8.07 Million USD | -235.479% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | -540.813% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 692.998% |
| IN8bio, Inc. | -16.38 Million USD | -65.355% |
| Kodiak Sciences Inc. | -103.87 Million USD | 73.911% |
| Annexon, Inc. | -193.75 Million USD | 86.013% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | 75377.778% |
| Assembly Biosciences, Inc. | -17.49 Million USD | -54.866% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | -671.42% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 102.57% |
| Eyenovia, Inc. | 1.25 Million USD | 2253.012% |
| Puma Biotechnology, Inc. | 26.9 Million USD | 200.725% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | -735.646% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 18.489% |
| Arcellx, Inc. | -296.95 Million USD | 90.874% |
| Cardiff Oncology, Inc. | -19.5 Million USD | -38.932% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 53.97% |
| Regulus Therapeutics Inc. | -20.72 Million USD | -30.747% |
| Moolec Science SA | 117.61 Thousand USD | 23141.083% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 29.425% |
| Geron Corporation | 14.76 Million USD | 283.592% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 28.53% |
| Royalty Pharma plc | 5.65 Billion USD | 100.479% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 80.837% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | -287.729% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | -405.327% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 80.743% |
| Humacyte, Inc. | -22.48 Million USD | -20.519% |
| Structure Therapeutics Inc. | -124.33 Million USD | 78.205% |
| 89bio, Inc. | -289.05 Million USD | 90.625% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | -7.361% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | -1419.91% |
| Genelux Corporation | -6.89 Million USD | -292.811% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 12.747% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | 132.417% |
| Notable Labs, Ltd. | -9.77 Million USD | -177.209% |
| Liquidia Corporation | -80.17 Million USD | 66.199% |
| Mustang Bio, Inc. | -3.73 Million USD | -625.375% |
| Immunovant, Inc. | -635.22 Million USD | 95.734% |
| Quantum-Si incorporated | -118.55 Million USD | 77.142% |
| Arbutus Biopharma Corporation | -17.56 Million USD | -54.293% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | -554.115% |
| Vera Therapeutics, Inc. | 8.02 Million USD | 437.611% |
| Acasti Pharma Inc. | -23 Million USD | -17.8% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | -704.816% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | -66.776% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 80.325% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | -769.604% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | -21.896% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | -45.942% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 83.991% |
| PepGen Inc. | -60.67 Million USD | 55.332% |
| Moleculin Biotech, Inc. | -22.97 Million USD | -17.949% |
| United Therapeutics Corporation | -507.7 Million USD | 94.662% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | -41.692% |
| Solid Biosciences Inc. | -47.75 Million USD | 43.246% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | -3043.527% |
| Immuneering Corporation | -54.94 Million USD | 50.676% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | -544.703% |
| Silo Pharma, Inc. | -3.52 Million USD | -668.945% |
| Belite Bio, Inc | -87.27 Million USD | 68.947% |
| XOMA Corporation | -29 Million USD | 6.552% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 61.667% |
| Bionomics Limited | 227 Million USD | 111.938% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 76.695% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | -969.878% |
| uniQure N.V. | -102.95 Million USD | 73.677% |
| Cassava Sciences, Inc. | -121.13 Million USD | 77.628% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | -550.593% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | 166.177% |
| Forte Biosciences, Inc. | -11.96 Million USD | -126.57% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | -775.832% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | 25666.038% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | -735.646% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 404.323% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | -265.426% |
| Altimmune, Inc. | -134.48 Million USD | 79.849% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 113.682% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | -969.878% |
| Compugen Ltd. | -12.9 Million USD | -110.012% |
| Peak Bio, Inc. | 10.34 Million USD | 362.085% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | -9475.972% |
| Benitec Biopharma Inc. | -50.58 Million USD | 46.424% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 74.027% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | 237.949% |
| Zura Bio Limited | -99.8 Million USD | 72.847% |
| PolyPid Ltd. | 6.17 Million USD | 539.222% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | 136.562% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | 237.949% |
| Instil Bio, Inc. | 75.35 Million USD | 135.962% |
| argenx SE | -2.02 Billion USD | 98.664% |
| Immunome, Inc. | -97.02 Million USD | 72.07% |
| Compass Therapeutics, Inc. | -22.49 Million USD | -20.471% |
| Verona Pharma plc | -220.44 Million USD | 87.707% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 62.226% |
| Shattuck Labs, Inc. | -121.42 Million USD | 77.682% |
| CervoMed Inc. | -7.79 Million USD | -247.755% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 85.391% |
| Plus Therapeutics, Inc. | -4.37 Million USD | -519.712% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 79.429% |
| Moolec Science SA | 117.61 Thousand USD | 23141.083% |
| Enveric Biosciences, Inc. | -2.28 Million USD | -1084.452% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | 270.458% |
| AnaptysBio, Inc. | -18.15 Million USD | -49.303% |
| Design Therapeutics, Inc. | -18.15 Million USD | -49.311% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 61.495% |
| NeurAxis, Inc. | 145.7 Thousand USD | 18699.863% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | 341.275% |
| Lumos Pharma, Inc. | -28.49 Million USD | 4.889% |
| Achilles Therapeutics plc | -126.92 Million USD | 78.649% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 62.226% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | -4032.799% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | -30.453% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | 1958.549% |
| Nutriband Inc. | -251.65 Thousand USD | -10668.626% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | -105.755% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | -264.247% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 107.966% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | 214.177% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 93.944% |
| Palisade Bio, Inc. | -12.06 Million USD | -124.654% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 80.686% |
| Beam Therapeutics Inc. | -262.72 Million USD | 89.685% |
| Neurogene Inc. | -131.95 Million USD | 79.463% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | 224.221% |
| AEON Biopharma, Inc. | -4.88 Million USD | -455.328% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 92.815% |
| Sesen Bio, Inc. | -112.55 Million USD | 75.922% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 72.862% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | -1054.276% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 30.559% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 67.46% |
| Athira Pharma, Inc. | -88.99 Million USD | 69.55% |
| Vaccinex, Inc. | -1.28 Million USD | -2004.037% |
| HCW Biologics Inc. | 2.85 Million USD | 1048.655% |
| XOMA Corporation | -29 Million USD | 6.552% |
| Nektar Therapeutics | 210.24 Million USD | 112.89% |
| Arvinas, Inc. | -313.8 Million USD | 91.364% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | 1769.861% |
| Merus N.V. | -192.88 Million USD | 85.95% |
| Omega Therapeutics, Inc. | 59.98 Million USD | 145.178% |
| Quince Therapeutics, Inc. | -6.93 Million USD | -290.602% |
| Rezolute, Inc. | -68.16 Million USD | 60.245% |
| Clene Inc. | 3.34 Million USD | 911.377% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | -105.505% |
| BeyondSpring Inc. | -13.75 Million USD | -97.019% |
| Synlogic, Inc. | -6.68 Million USD | -305.385% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | 2489.771% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | -220.52% |
| Peak Bio, Inc. | 10.34 Million USD | 362.085% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 67.12% |
| Krystal Biotech, Inc. | -350.23 Million USD | 92.262% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | 121.833% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 83.964% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | -758.371% |
| MannKind Corporation | 143.89 Million USD | 118.833% |
| Ikena Oncology, Inc. | -109.15 Million USD | 75.173% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | -257.945% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 18.127% |
| Gossamer Bio, Inc. | 180.35 Million USD | 115.026% |
| CohBar, Inc. | -5.93 Million USD | -356.942% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 8.901% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 693.517% |
| Legend Biotech Corporation | -949.39 Million USD | 97.146% |
| Mural Oncology plc | -255.84 Million USD | 89.408% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 184.122% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | -475.293% |
| Disc Medicine, Inc. | -358.28 Million USD | 92.436% |
| Champions Oncology, Inc. | 4.81 Million USD | 663.175% |
| REGENXBIO Inc. | 54.76 Million USD | 149.481% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | -9977.834% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 82.056% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | -200.71% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 66.412% |
| Vaxart, Inc. | -8.24 Million USD | -228.844% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 45.994% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 78.689% |
| Cellectis S.A. | -43.85 Million USD | 38.205% |
| Longeveron Inc. | -2.9 Million USD | -831.912% |
| Repare Therapeutics Inc. | -107.85 Million USD | 74.874% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 102.798% |
| Inozyme Pharma, Inc. | 12 Million USD | 325.758% |
| Revolution Medicines, Inc. | -608.2 Million USD | 95.544% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | -2103.252% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 89.778% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 81.942% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | -73.196% |
| Anixa Biosciences, Inc. | -740 Thousand USD | -3562.162% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 99.717% |
| Denali Therapeutics Inc. | -74.86 Million USD | 63.802% |
| Revelation Biosciences, Inc. | -11.99 Million USD | -125.99% |
| Veru Inc. | 4.77 Million USD | 666.949% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | -140.975% |
| Cingulate Inc. | 3.08 Million USD | 979.104% |
| Passage Bio, Inc. | 4.58 Million USD | 691.058% |
| Context Therapeutics Inc. | -14.44 Million USD | -87.545% |
| Exicure, Inc. | 5.84 Million USD | 563.327% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 88.237% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 31.514% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | 272.71% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 53.928% |
| Nuvalent, Inc. | -335.38 Million USD | 91.92% |
| ABVC BioPharma, Inc. | 1.73 Million USD | 1662.553% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 63.615% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | -204.837% |
| OmniAb, Inc. | 9.2 Million USD | 394.469% |
| Anew Medical, Inc. | 1.43 Million USD | 1991.844% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | 265.428% |
| Lipocine Inc. | -4.75 Million USD | -469.975% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 75.325% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | 277.927% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 46.505% |
| G1 Therapeutics, Inc. | 24.89 Million USD | 208.87% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | -303.214% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 58.831% |
| Ocugen, Inc. | -32.52 Million USD | 16.669% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 68.332% |
| Q32 Bio Inc. | -37.94 Million USD | 28.586% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | -4215.287% |
| Alumis Inc. Common Stock | -13.52 Million USD | -100.31% |
| Equillium, Inc. | -22.39 Million USD | -21.025% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | -5.992% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 16.939% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | -10831.166% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 120.218% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 947.405% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | 8351.101% |
| Dominari Holdings Inc. | 195 Thousand USD | 13997.436% |
| Edesa Biotech, Inc. | -5.26 Million USD | -414.533% |
| vTv Therapeutics Inc. | -8.91 Million USD | -203.914% |
| Bio-Techne Corporation | 267.74 Million USD | 110.121% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | -67.191% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 77.052% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | -222.504% |
| Candel Therapeutics, Inc. | -12.65 Million USD | -114.212% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 88.944% |
| Nkarta, Inc. | 57.29 Million USD | 147.296% |
| BioCardia, Inc. | 212 Thousand USD | 12883.019% |
| Iterum Therapeutics plc | 13.43 Million USD | 301.667% |